Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Ultragenyx Pharmaceutical heads into its November earnings with a notable disconnect: short sellers remain heavily positioned, yet options traders have swung sharply toward calls at a rate not seen all year.
The short side of the ledger tells a crowded story. Short interest is running at 17.4% of the free float, up roughly 4% over the past month and near multi-week highs after briefly retreating in mid-September. The ORTEX short score has ticked to 56.3, its highest reading in the past ten sessions. Yet the borrow market offers no squeeze signal. At 0.48%, the cost to borrow is low and has eased about 13% on the week. Availability is ample, with roughly 64.5 million shares still available to lend against the 16.7 million currently borrowed, giving an availability ratio near 872%. Even at the 52-week tightest point, availability only dipped to around 705%, meaning lenders have never been meaningfully strained. The short thesis here is not a trapped, forced position; it is an expression of fundamental doubt that the market is perfectly happy to fund.
Options positioning has flipped the other way, sharply. The put/call ratio has collapsed to 0.32, almost one standard deviation below its 20-day average of 0.53, and is sitting at its lowest reading in the past 52 weeks. For context, that same ratio was above 1.9 throughout late August. The shift happened fast, compressing from deeply defensive in early September to almost entirely call-dominated in a matter of weeks. That is a significant change in tone from options participants, even as the stock closed Tuesday at $14.46, down 5.6% on the week and 5.5% on the month.
The Street is split but has been lifting targets. A cluster of analysts raised price targets around September 17 to 18, with Citigroup, Canaccord Genuity, and Cantor Fitzgerald all moving targets higher while holding positive ratings. Barclays, maintaining an Overweight, moved its target from $32 to $35 on September 21. Morgan Stanley, at Equal-Weight, lifted from $18 to $20 the same week. The mean analyst target is around $28, implying meaningful upside from current levels, though the range is wide and the gap between the stock price and the consensus reflects how far the stock has fallen rather than fresh conviction. Goldman Sachs cut its target sharply, from $28 to $19, on September 4, staying Neutral. The bull case centres on Crysvita's revenue potential, two priority review vouchers that could generate roughly $400 million in non-dilutive capital, and a gene-therapy pipeline anchored by DTX401 and UX701. Bears point to lower-than-expected commercial drug revenues, the loss of GTX-102 following the ASPIRE failure, high operating costs, and reimbursement pressure on gene therapies. The forward EPS trajectory factor ranks in the 96th percentile, reflecting sharp upward revisions to longer-dated estimates, but near-term EPS momentum scores rank in the bottom decile, in the 4th and 5th percentile over 30 and 90 days respectively.
On the ownership side, BlackRock lifted its disclosed stake to 8.3% as of a July 13D/G amendment, up from 5.1%, and the most recent institutional data shows it holding over 10.6 million shares as of September 30. RTW Investments disclosed a fresh 7.9% stake in August, making it the second-largest holder on record. No 13D activist is on the register. Insider activity has been one-directional: every open-market transaction in the past 90 days has been a sale, with net disposals of roughly 12,700 shares worth about $340,000. Most trades are under 10b5-1 plans and involve modest dollar amounts, suggesting scheduled diversification rather than conviction selling, but the absence of any buying is worth noting given where the stock is trading.
The alt data layer flags one relevant data point: Medicaid reimbursements for Ultragenyx drugs were down 10% year-on-year in the quarter ending January 2026, at roughly $9.3 million. No dataset in ORTEX's coverage has been measured to lead the company's reported figures, so the reading is colour rather than a directional signal. Retail attention has been elevated, with Wikipedia page views and ORTEX stock page traffic running at a z-score of 3.3 against the company's own 90-day history, as of late September.
The next earnings print is scheduled for November 3. With shorts entrenched, targets freshly lifted, and options traders now leaning hard into calls, the key question heading into that date is whether the commercial revenue trajectory can begin to close the gap between where the stock trades and where the Street thinks it belongs.
See the live data behind this article on ORTEX.
Open RARE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
